On November 29, 2022 Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") reported it has reached an important recruitment milestone in the Company’s ACCENT clinical trial in frontline patients with pancreatic cancer (Press release, Amplia Therapeutics, NOV 29, 2022, View Source;[email protected] [SID1234624555]). This week, enrolment of the first cohort of patients was completed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first stage of the ACCENT trial is designed to test ascending doses of AMP945 given in combination with standard gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer. Cohorts of patients (three per cohort) are given the same dose of AMP945 in addition to standard chemotherapy so that safety, tolerability, pharmacokinetics and pharmacodynamics of the combined therapy can be assessed. After 1 month of treatment, the trial’s Safety Committee will review the clinical data collected for each cohort and, subject to the data, authorise dose escalation of AMP945 in a subsequent cohort.
Amplia’s CEO and Managing Director Dr John Lambert commented that "This month, we have opened four additional ACCENT clinical trial sites, taking our total number of sites to seven. There has been a lot of interest in the ACCENT clinical trial and we expect that recruitment rates will accelerate as the trial builds further momentum. We are delighted to have reached today’s recruitment milestone and we will make further announcements as we reach future milestones and dose escalate AMP945. As ever, our thanks go to the patients who have consented to participate in the ACCENT trial."
This ASX announcement has been approved and authorised for release by the Board of Amplia Therapeutics.